Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

HIV-Positive livers for HIV-Positive patients: a new hope?

NCT ID NCT07665372

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 10, 2026 · Updated 3 times

Summary

This study looks at whether people with HIV who need a liver transplant can safely receive a liver from a donor who also had HIV. Researchers will compare infections and cancer rates between those who get an HIV-positive donor liver and those who get an HIV-negative donor liver. The goal is to see if using HIV-positive organs is a safe option to help more people get transplants faster.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
liver transplant from a donor with HIV
What this could lead to
If successful, this could show that using livers from HIV-positive donors is safe and effective for people with HIV, expanding the donor pool and reducing wait times.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. There may be higher risks of infections or cancer in recipients of HIV-positive donor livers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant meets local criteria for liver or simultaneous liver kidney (SLK) transplant. * Participant or legally authorized representative (in accordance with Johns Hopkins Medicine Institutional Review Board (IRB) and local IRB policy) is able to understand and provide informed consent. * Participant has documented HIV infection by any licensed assay or documented history of detectable HIV-1 RNA. * Participant is ≥ 18 years old. * Most recent HIV-1 RNA \< 50 copies RNA/mL. Viral blips between 50-400 copies will be allowed as long as there are not consecutive measurements \> 200 copies/mL. Organ recipients who are unable to tolerate Antiretroviral Therapy (ART) due to organ failure or recently started ART may be eligible despite a detectable viral load if safe and effective ART to be used by the recipient after transplantation is described. Exclusion Criteria: * Participant has prior progressive multifocal leukoencephalopathy (PML), cryptosporidiosis of \> 1 month duration, or prior primary Central Nervous System (CNS) lymphoma. * Participant is pregnant or breastfeeding. * Past or current medical problems or findings from medical history, physical examination, or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    NOT_YET_RECRUITING

    Los Angeles, California, 90048, United States

  • Emory University

    NOT_YET_RECRUITING

    Atlanta, Georgia, 30322, United States

  • Houston Methodist Research Institute

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Icahn School of Medicine at Mount Sinai

    RECRUITING

    New York, New York, 10029, United States

  • Johns Hopkins University

    RECRUITING

    Baltimore, Maryland, 21205, United States

  • Massachusetts General Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic, Arizona

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic, Florida

    NOT_YET_RECRUITING

    Jacksonville, Florida, 32224, United States

  • New York University School of Medicine

    NOT_YET_RECRUITING

    New York, New York, 10016, United States

  • Northwestern University

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

  • Ochsner Clinic Foundation

    NOT_YET_RECRUITING

    Jefferson, Louisiana, 70121, United States

  • Ohio State University Medical Center

    NOT_YET_RECRUITING

    Columbus, Ohio, 43210, United States

  • University of California, San Francisco

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

  • University of Cincinnati

    NOT_YET_RECRUITING

    Cincinnati, Ohio, 45229, United States

  • University of Colorado Anschutz

    NOT_YET_RECRUITING

    Aurora, Colorado, 80045, United States

  • University of Miami, Miami Transplant Institute

    NOT_YET_RECRUITING

    Miami, Florida, 33136, United States

  • University of Pittsburgh Medical Center

    NOT_YET_RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

  • University of Texas Southwestern Medical Center

    NOT_YET_RECRUITING

    Dallas, Texas, 75390, United States

  • Weill Cornell Medical College

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.